Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (91-100 of 208) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2017
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 StudyPatrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019Paolo A Ascierto, Carlo Bifulco, Jerome Galon, et al.
The Lancet. Oncology|February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2012
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumorsLee S Rosen, Igor Puzanov, Gregory Friberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2017
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell CarcinomaVivek Narayan, Stephen Keefe, Naomi Haas, et al.
Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.
Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
Investigational New Drugs|October 9, 2014
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsIgor Puzanov, Jeffrey Sosman, Armando Santoro, et al.
Pageof 21

Showing results (91-100 of 208) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2017
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 StudyPatrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019Paolo A Ascierto, Carlo Bifulco, Jerome Galon, et al.
The Lancet. Oncology|February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2012
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumorsLee S Rosen, Igor Puzanov, Gregory Friberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2017
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell CarcinomaVivek Narayan, Stephen Keefe, Naomi Haas, et al.
Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.
Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
Investigational New Drugs|October 9, 2014
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsIgor Puzanov, Jeffrey Sosman, Armando Santoro, et al.
Pageof 21